Abdom Radiol (NY)

1. ASLAN S, Tasdemir MN, Cakir E, Oguz U, et al
   Predicting variant histology in bladder cancer: the role of multiparametric MRI and vesical imaging-reporting and data system (VI-RADS).
   Abdom Radiol (NY). 2025 Mar 18. doi: 10.1007/s00261-025-04852.
   

   >> Share

   
   

   
   Acta Biomater

2. XU J, Xu J, Sun C, He X, et al
   Effective Delivery of CRISPR/dCas9-SAM for Multiplex Gene Activation Based on Mesoporous Silica Nanoparticles for Bladder Cancer Therapy.
   Acta Biomater. 2025 Mar 18:S1742-7061(25)00205.
   

   >> Share

   
   

   
   Actas Urol Esp (Engl Ed)

3. MANCON S, Matsukawa A, Cadenar A, Tsuboi I, et al
   Impact of opium on bladder cancer incidence: A systematic review and meta-analysis.
   Actas Urol Esp (Engl Ed). 2025 Mar 15:501749. doi: 10.1016/j.acuroe.2025.501749.
   

   >> Share

   
   
4. MERO S, Oberneder K, Weiss J, Grobet-Jeandin E, et al
   Radiofrequency induced hyperthermia in non-muscle invasive bladder cancer: Oncologic outcomes in a real-world scenario.
   Actas Urol Esp (Engl Ed). 2025 Mar 17:501746. doi: 10.1016/j.acuroe.2025.501746.
   

   >> Share

   
   

   
   Adv Sci (Weinh)

5. ZHAO H, Gao X, Jiang Y, Yu Y, et al
   Targeting COPA to Enhance Erdafitinib Sensitivity in FGFR-Altered Bladder Cancer.
   Adv Sci (Weinh). 2025 Mar 20:e2413209. doi: 10.1002/advs.202413209.
   

   >> Share

   
   
6. ZHANG X, Chen Z, He X, Wang J, et al
   SUMOylation of SETD8 Promotes Tumor Growth by Methylating and Stabilizing MYC in Bladder Cancer.
   Adv Sci (Weinh). 2025 Mar 16:e2501734. doi: 10.1002/advs.202501734.
   

   >> Share

   
   

   
   Am J Transl Res

7. ZHANG L, Chen Y, Liao H
   Efficacy and safety of Solifenacin combined with Mirabegron in treating overactive bladder in female patients following bladder instillation for bladder cancer.
   Am J Transl Res. 2025;17:1144-1152.
   

   >> Share

   
   

   
   Ann Med Surg (Lond)

8. KHATTAK AA, Javed A, Pokhrel P, Mukhtar S, et al
   Transforming non-muscle invasive bladder cancer (NMIBC) treatment: FDA approval of Anktiva in combination with BCG.
   Ann Med Surg (Lond). 2025;87:457-459.
   

   >> Share

   
   

   
   Biochem Genet

9. DAI C, Li Q, Wang L, Zhang J, et al
   Correction: FENDRR Represses Bladder Cancer Cell Proliferation, Stemness, Migration, Invasion, and EMT Process by Targeting miR-18a-5p/AFF4 Axis.
   Biochem Genet. 2025 Mar 15. doi: 10.1007/s10528-025-11065.
   

   >> Share

   
   

   
   Biochim Biophys Acta Gen Subj

10. ALMEIDA P, Alves I, Fernandes A, Lima C, et al
    "Mannose glycans as key players in trained immunity: A novel anti-tumoral catalyst".
    Biochim Biophys Acta Gen Subj. 2025;1869:130779.
    

    >> Share

    
    

    
    Biochim Biophys Acta Mol Basis Dis

11. CHEN L, He C, Ou Z, Zhao C, et al
    TNF-alpha drives bladder cancer metastasis via METTL3-mediated m6A modification to promote CLASP2/IQGAP1-dependent cytoskeleton remodeling.
    Biochim Biophys Acta Mol Basis Dis. 2025 Mar 19:167811.
    

    >> Share

    
    

    
    Biosens Bioelectron

12. CHENG M, Zhang L, Han X, Xu H, et al
    High-fidelity telomerase activity assay based on light-triggered nucleic acid separation system for the diagnosis of bladder cancer.
    Biosens Bioelectron. 2025;278:117355.
    

    >> Share

    
    

    
    Bladder Cancer

13. MIYAKE M, Iida K, Nishimura N, Ohnishi S, et al
    Serum metabolomic analysis identified serum biomarkers predicting tumour recurrence after Bacillus Calmette-Guerin therapy in patients with non-muscle invasive bladder cancer.
    Bladder Cancer. 2025;11:23523735251325100.
    

    >> Share

    
    

    
    BMC Cancer

14. SHENG Z, Xu J, Wang M, Xu X, et al
    The role of urinary microbiota in primary and recurrent bladder cancer: insights from a propensity score matching study.
    BMC Cancer. 2025;25:468.
    

    >> Share

    
    

    
    BMC Urol

15. MOU Y, Mao Y, Liu Z, Zhang P, et al
    Robot-assisted radical cystectomy with the clinical application of "Y-shaped" end-to-side ureteral anastomosis in elderly and obese patients.
    BMC Urol. 2025;25:56.
    

    >> Share

    
    

    
    Cancer Biomark

16. ZHANG X, Zhang B, He Y, Xiong W, et al
    A nomogram based on preoperative NLR predicts distant metastasis of urothelial carcinoma of the bladder.
    Cancer Biomark. 2024;41.
    

    >> Share

    
    

    
    Cancer Treat Rev

17. GRANDE E, Hussain SA, Barthelemy P, Kanesvaran R, et al
    Individualizing first-line treatment for advanced urothelial carcinoma: A favorable dilemma for patients and physicians.
    Cancer Treat Rev. 2025;134:102900.
    

    >> Share

    
    

    
    Clin J Gastroenterol

18. HOTTA Y, Yoshioka N, Sakamoto A, Inagaki M, et al
    Late-onset disseminated BCG infection with hepatosplenomegaly after intravesical BCG immunotherapy in a non-immunocompromised patient.
    Clin J Gastroenterol. 2025;18:337-342.
    

    >> Share

    
    

    
    Clin Microbiol Rev

19. JIAN N, Yu L, Ma L, Zheng B, et al
    BCG therapy in bladder cancer and its tumor microenvironment interactions.
    Clin Microbiol Rev. 2025 Mar 20:e0021224. doi: 10.1128/cmr.00212.
    

    >> Share

    
    

    
    Clin Transl Oncol

20. GUTIERREZ PEREZ C, Lastra Aras E, Saiz Lopez P, Garcia Toro E, et al
    Single-center analysis of a real-world cohort of patients with metastatic urothelial carcinoma evaluated by NGS: molecular landscape and efficacy of targeted therapies.
    Clin Transl Oncol. 2025;27:1211-1220.
    

    >> Share

    
    

    
    Cureus

21. ALQARNI KA
    Recent Advances in Immunotherapy for Bladder Cancer Treatment.
    Cureus. 2025;17:e79002.
    

    >> Share

    
    

    
    Curr Med Imaging

22. HE X, Chen Y, Zhou S, Wang G, et al
    A Machine Learning Model Based on Multi-Phase Contrast-enhanced CT for the Preoperative Prediction of the Muscle-Invasive Status of Bladder Cancer.
    Curr Med Imaging. 2025 Mar 17. doi: 10.2174/0115734056377754250304040058.
    

    >> Share

    
    

    
    Curr Probl Cancer

23. THAKUR A, Kumar L, Agarwal S, Tripathy R, et al
    Assessing the clinical efficacy of neoadjuvant intravesical Mitomycin C in naive non-muscle invasive urinary bladder cancer: A systematic review and meta-analysis.
    Curr Probl Cancer. 2025 Mar 17:101198.
    

    >> Share

    
    

    
    EClinicalMedicine

24. JIANG F, Hong G, Zeng H, Lin Z, et al
    Deep learning-based model for prediction of early recurrence and therapy response on whole slide images in non-muscle-invasive bladder cancer: a retrospective, multicentre study.
    EClinicalMedicine. 2025;81:103125.
    

    >> Share

    
    

    
    Ecotoxicol Environ Saf

25. KOBAYASHI S, Kashiwagi H, Kobayashi K, Kohzaki M, et al
    4,4'-methylenebis(2-chloroaniline) induces chromosome aneuploidy associated with premature chromatid separation in mammalian cells: A possible carcinogenic mechanism.
    Ecotoxicol Environ Saf. 2025;293:117981.
    

    >> Share

    
    

    
    Environ Toxicol

26. TUNG MC, Chang GM, Dai WC, Hsu CH, et al
    Cryptotanshinone Suppresses the STAT3/BCL-2 Pathway to Provoke Human Bladder Urothelial Carcinoma Cell Death.
    Environ Toxicol. 2025;40:624-635.
    

    >> Share

    
    

    
    Eur J Surg Oncol

27. ALBISINNI S, Orecchia L, Mjaess G, Aoun F, et al
    Enhanced Recovery After Surgery for patients undergoing radical cystectomy: Surgeons' perspectives and recommendations ten years after its implementation.
    Eur J Surg Oncol. 2025;51:109543.
    

    >> Share

    
    

    
    Eur Urol

28. VAN DER HEIJDEN AG, Bruins HM, Carrion A, Cathomas R, et al
    European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2025 Guidelines.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00138-1. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
29. VAN DOEVEREN T, Aben KKH, van Leeuwen PJ, Boormans JL, et al
    Reply to Alexandra Masson-Lecomte. Bladder Cancer Recurrence Following Management of Upper Tract Urothelial Carcinoma: Balancing Prevention and Iatrogenicity. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2025.01.004.
    Eur Urol. 2025 Mar 17:S0302-2838(25)00151-4. doi: 10.1016/j.eururo.2025.
    

    >> Share

    
    
30. KOSHKIN VS, Danchaivijitr P, Bae WK, Semenov A, et al
    Pembrolizumab Retreatment in Patients with Advanced or Metastatic Urothelial Carcinoma Who Responded to First-course Pembrolizumab-based Therapy.
    Eur Urol. 2025;87:390-395.
    

    >> Share

    
    

    
    FEBS J

31. CHEN X, Diao W, Guo X, Cao W, et al
    The N6-methyladenosine reader IGF2BP3 promotes bladder cancer progression through enhancing HSP90AB1 expression.
    FEBS J. 2025 Mar 19. doi: 10.1111/febs.70068.
    

    >> Share

    
    

    
    Front Oncol

32. XIAO J, Liu W, Gong J, Lai W, et al
    Integrated single-cell analysis reveals the regulatory network of disulfidptosis-related lncRNAs in bladder cancer: constructing a prognostic model and predicting treatment response.
    Front Oncol. 2025;15:1527036.
    

    >> Share

    
    

    
    Hereditas

33. DAI H, Zhang X, Zhao Y, Nie J, et al
    ADME gene-driven prognostic model for bladder cancer: a breakthrough in predicting survival and personalized treatment.
    Hereditas. 2025;162:42.
    

    >> Share

    
    

    
    Int J Surg Pathol

34. MISHRA M, Ayyanar P, Tripathy SR, Das MK, et al
    Urothelial Carcinoma with Trophoblastic Differentiation-A Report with Review.
    Int J Surg Pathol. 2025;33:490-494.
    

    >> Share

    
    
35. KAYRAKLIOGLU N, Chan E, Bastian B, Long SR, et al
    Primary Melanoma of the Urinary Bladder: Clinical, Histopathologic, and Comprehensive Molecular Analysis of a Rare Tumor.
    Int J Surg Pathol. 2025;33:477-483.
    

    >> Share

    
    

    
    Int J Urol

36. TAGUCHI S, Kawai T, Ambe Y, Kishitani K, et al
    Physical, but not laboratory, treatment-related adverse events are associated with favorable outcomes of enfortumab vedotin for advanced urothelial carcinoma: A landmark analysis.
    Int J Urol. 2025;32:270-276.
    

    >> Share

    
    

    
    J Am Acad Dermatol

37. SCHONMANN Y, Cohen NT, Czarnowicki T
    Evaluating cancer risk in a large cohort of 25,008 patients with vitiligo: Insights from a comprehensive cohort population-based study.
    J Am Acad Dermatol. 2025;92:741-752.
    

    >> Share

    
    

    
    J Cell Mol Med

38. XIE X, He H, Zhang N, Wang X, et al
    DDR1 Targeting HOXA6 Facilitates Bladder Cancer Progression via Inhibiting Ferroptosis.
    J Cell Mol Med. 2025;29:e70410.
    

    >> Share

    
    

    
    J Control Release

39. FA YC, Chen CC, Liu YC, Lu YH, et al
    Precise identification of bladder tumors utilizing mucoadhesive thiolated hollow mesoporous silica nanoparticles.
    J Control Release. 2025;380:1127-1140.
    

    >> Share

    
    

    
    J Endourol

40. LI KP, Wang L, Wan S, Wang CY, et al
    Enhanced Artificial Intelligence in Bladder Cancer Management: A Comparative Analysis and Optimization Study of Multiple Large Language Models.
    J Endourol. 2025 Mar 18. doi: 10.1089/end.2024.0860.
    

    >> Share

    
    

    
    J Immunother Cancer

41. GALARZA FORTUNA GM, Grass D, Maughan BL, Jain RK, et al
    Nivolumab adjuvant to chemo-radiation in localized muscle-invasive urothelial cancer: primary analysis of a multicenter, single-arm, phase II, investigator-initiated trial (NEXT).
    J Immunother Cancer. 2025;13:e010572.
    

    >> Share

    
    

    
    J Thromb Haemost

42. WALKER GE, Borroni E, Haider R, Olgasi C, et al
    Factor VIII a coagulation co-factor is a relevant survival factor in bladder cancer cell lines.
    J Thromb Haemost. 2025 Mar 12:S1538-7836(25)00142.
    

    >> Share

    
    

    
    J Urol

43. STOVER AM, Mueller D, Carda-Auten J, Hilton A, et al
    Perceived Impact on Patient Routines/Responsibilities for Surgery and a Nonsurgical Primary Treatment Option in Recurrent Low-Grade Intermediate-Risk Nonmuscle-Invasive Bladder Cancer: Findings From the ENVISION Phase 3 Trial.
    J Urol. 2025 Mar 6:101097JU0000000000004511. doi: 10.1097/JU.0000000000004511.
    

    >> Share

    
    

    
    JMIR Cancer

44. LIN S, Duan L, Xu X, Cao H, et al
    Analyzing Online Search Trends for Kidney, Prostate, and Bladder Cancers in China: Infodemiology Study Using Baidu Search Data (2011-2023).
    JMIR Cancer. 2025;11:e57414.
    

    >> Share

    
    

    
    Mater Today Bio

45. SHI Y, Fan G, Yang E, Zhang Y, et al
    Enhanced efficacy of immune checkpoint inhibitors by folate-targeted multifunctional drug through synergistic therapy inducing ferroptosis and immunogenic cell death in bladder cancer.
    Mater Today Bio. 2025;31:101584.
    

    >> Share

    
    

    
    Mod Pathol

46. DERNBACH G, Eich ML, Dragomir MP, Anders P, et al
    Spatial expression of HER2, NECTIN4, and TROP-2 in Muscle-Invasive Bladder Cancer and metastases: Implications for pathological and clinical management.
    Mod Pathol. 2025 Mar 12:100753. doi: 10.1016/j.modpat.2025.100753.
    

    >> Share

    
    

    
    Nutr Cancer

47. YU F, Yu N, Zhang L, Xu X, et al
    Emodin Decreases Tumor-Associated Macrophages Accumulation and Suppresses Bladder Cancer Development by Inhibiting CXCL1 Secretion from Cancer-Associated Fibroblasts.
    Nutr Cancer. 2025 Mar 20:1-16. doi: 10.1080/01635581.2025.2480309.
    

    >> Share

    
    

    
    Oncol Res

48. MIHAI IM, Wang G
    Biomarkers for predicting bladder cancer therapy response.
    Oncol Res. 2025;33:533-547.
    

    >> Share

    
    
49. FRANCESCA B, Meo M, Giudice FD, Scornajenghi CM, et al
    Exploring the utility of a NGS multigene panel to predict BCG response in patients with non-muscle invasive bladder cancer.
    Oncol Res. 2025;33:723-731.
    

    >> Share

    
    

    
    Pharmacol Res

50. WANG C, Wan S, Li K, Chen S, et al
    TPI1 promotes p53 ubiquitination in bladder cancer by recruiting AKT to enhance MDM2 phosphorylation.
    Pharmacol Res. 2025;215:107695.
    

    >> Share

    
    

    
    Photodiagnosis Photodyn Ther

51. TAOKA R, Fukuhara H, Miyake M, Kobayashi K, et al
    Efficacy of photodynamic diagnosis for non-muscle invasive bladder cancer: Exploratory subject-based analysis in a prospective, single-arm, multicenter phase III trial.
    Photodiagnosis Photodyn Ther. 2025;53:104554.
    

    >> Share

    
    

    
    Res Rep Urol

52. BEN MUVHAR R, Paluch R, Mekayten M
    Recent Advances and Emerging Innovations in Transurethral Resection of Bladder Tumor (TURBT) for Non-Muscle Invasive Bladder Cancer: A Comprehensive Review of Current Literature.
    Res Rep Urol. 2025;17:69-85.
    

    >> Share

    
    

    
    Sci Rep

53. INCORVAIA L, Scagliarini S, Marques Monteiro FS, Takeshita H, et al
    Sex as modifier of survival in patients with advanced urothelial cancer treated with pembrolizumab.
    Sci Rep. 2025;15:8815.
    

    >> Share

    
    
54. LI B, Gan J, Li T, Chen J, et al
    Comprehensive analysis of RNA methylation-related genes to identify molecular cluster for predicting prognosis and immune profiles in bladder cancer.
    Sci Rep. 2025;15:9147.
    

    >> Share

    
    

    
    Transl Androl Urol

55. AVUDAIAPPAN AP, Prabhakar P, Fleischmann B, Rubens M, et al
    Survival analysis comparing bladder preservation techniques in octogenarians with muscle-invasive bladder cancer.
    Transl Androl Urol. 2025;14:280-288.
    

    >> Share

    
    

    
    Transl Cancer Res

56. LIU Z, Zhang H, Luo R, Wang B, et al
    Clinical characterization and prognostic modeling of bladder cancer patients with a history of prior tumors: a SEER database analysis.
    Transl Cancer Res. 2025;14:1111-1123.
    

    >> Share

    
    

    
    World J Urol

57. SLUSARCZYK A, Scilipoti P, Marcq G, Pradere B, et al
    Comparison of extended and standard lymph node dissection in radical cystectomy for urothelial bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2025;43:181.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share